|
|
|
|
| LEADER |
01556nam a2200289 u 4500 |
| 001 |
EB001874806 |
| 003 |
EBX01000000000000001038173 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
191026 r ||| eng |
| 245 |
0 |
0 |
|a Screening for chlamydia trachomatis and neisseria gonorrhoeae during pregnancy
|h Elektronische Ressource
|b project protocol
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2018, February 2018
|
| 300 |
|
|
|a 1 PDF file (40 pages)
|b illustrations
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Sexually Transmitted Diseases, Bacterial / diagnosis
|
| 653 |
|
|
|a Pregnancy Complications
|
| 653 |
|
|
|a Chlamydia trachomatis
|
| 653 |
|
|
|a Neisseria gonorrhoeae
|
| 653 |
|
|
|a Practice Guidelines as Topic
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH health technology assessment report
|
| 500 |
|
|
|a "PROSPERO Registration Number: CRD42018087016
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK540453
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this HTA is to address the policy question through an assessment of the clinical effectiveness and safety, and cost-effectiveness, and patients', partners', and health care providers' perspectives and experiences regarding the screening of pregnant persons for CT and GC. An analytic framework for the HTA can be found in Appendix 1
|